The Data Protection Act (1998): implications for health researchers.

J Adv Nurs

Clinical Governance Research and Development Unit, Department of General Practice and Primary Health Care, Leicester Warwick Medical School, University of Leicester, Leicester LE5 4PW, UK.

Published: August 2001

Aims: This paper reports on the methods used in two studies to obtain access to subjects to comply with the common law duty of confidence laid out in the Data Protection Act (1998) and discusses the researchers' problems in interpreting the procedures.

Rationale: The amendments to the United Kingdom (UK) Data Protection Act (1998) are causing confusion within the health service and academic institutions. There is a need to balance patient confidentiality with the requirement to conduct vital, unbiased research in which health service professionals are not subject to ethical dilemmas. This paper examines the recruitment methods used in two studies in which the researchers' attempts to adhere to the requirements lengthened the study costs and may have produced less reliable results.

Methods: The methodological difficulties in two studies are presented. In Study 1, the difficulties encountered when the Multicentre Research Ethics Committee refused permission for researchers to recruit patients directly to a multicentre randomized controlled trial are discussed. In Study 2, the method used to compile a sampling frame for a national questionnaire survey following the eight principles of the Act are described.

Findings: Our experience has shown that health care professionals are increasingly required to recruit patients to intervention trials, and that researchers are not allowed access to the names of patients or other subjects to ask them for consent to participate in a study. The requirement for researchers to use "intermediaries" to obtain consent from and recruit subjects to studies increases the risk of selection bias, may expose the practitioner to ethical difficulties and may compromise the external validity of trial results. There is also a danger that research costs will soar when the Data Protection Act (1998) is fully realized.

Conclusion: The Data Protection Act (1998) is currently being interpreted in a number of different ways. We conclude there is an urgent need for consensus within the health service and academic communities.

Download full-text PDF

Source
http://dx.doi.org/10.1046/j.1365-2648.2001.01867.xDOI Listing

Publication Analysis

Top Keywords

data protection
20
protection 1998
20
health service
12
methods studies
8
service academic
8
recruit patients
8
data
5
0
5
health
5
1998 implications
4

Similar Publications

Carvacrol: Innovative Synthesis Pathways and Overview of its Patented Applications.

Recent Pat Biotechnol

January 2025

Chemical Science and Engineering Research Team (ERSIC), Department of Chemistry, Polydisciplinary Faculty of Beni Mellal (FPBM), Sultan Moulay Slimane University (USMS), P.O. Box 592 Mghila, Beni Mellal 23000, Morocco.

Aim: This research concerns the patentability of carvacrol; it could be helpful for researchers to easily identify any innovation in the biotechnological application of this monoterpene as well as other similar compounds.

Background: Like thyme or oregano, several plants in the Lamiaceae family produce carvacrol. It is one of the secondary metabolites with several biological activities, including the improvement in plants' resistance and their protection.

View Article and Find Full Text PDF

The application of artificial intelligence (AI) to healthcare in Africa has the potential to transform productivity, diagnosis, disease surveillance, and resource allocation by improving accuracy and efficiency. However, to fully realize its benefits, it is necessary to consider issues concerning data privacy, equity, infrastructure integration, and ethical policy development. The use of these tools may improve the detection of diseases, the distribution of resources, and the continuity of care.

View Article and Find Full Text PDF

Angiotensin receptor-neprilysin inhibitors (ARNIs) represent a novel class of medications characterized by their dual action on major cardiorenal regulators, specifically the renin-angiotensin system (RAS) and the natriuretic peptide (NP) system. Sacubitril/valsartan, a pioneering ARNI, has demonstrated strong antihypertensive effect as well as superior efficacy in preserving renal function compared to RAS inhibitors in heart failure patients with reduced ejection fraction. Here, we gathered evidence on the impact of sacubitril/valsartan on the preservation of kidney function in patients with cardiorenal syndrome (CRS).

View Article and Find Full Text PDF

Chemical industries are highly vulnerable to accidental events or terrorist attacks due to their processing, storage, and transportation of explosive, flammable, and toxic materials. Major industrial risks include fire, explosion, and toxic chemical release. An effective risk evaluation system is essential to prevent accidents or terrorist attacks.

View Article and Find Full Text PDF

Background: National health systems in Europe are facing similar challenges - demographic change, a rising burden of disease due to chronic non-communicable diseases, and health inequalities. Comparable health data and knowledge sharing between countries are therefore an important basis for policy decision-making. However, health information in the European Union (EU) is fragmented and approaches to establishing a comprehensive system are largely project-based.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!